PMID- 22631597
OWN - NLM
STAT- MEDLINE
DCOM- 20130429
LR  - 20120727
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 80
IP  - 2
DP  - 2012 Aug
TI  - Evaluation of humoral immune response to donor HLA after implantation of 
      cellularized versus decellularized human heart valve allografts.
PG  - 165-74
LID - 10.1111/j.1399-0039.2012.01885.x [doi]
AB  - We have evaluated the development of antibodies in response to donor allograft 
      valve implant in patients who received cellularized and decellularized allografts 
      and determined possible immunogenic epitopes considered responsible for 
      antibodies reactivity. Serum samples from all recipients who received 
      cellularized allografts or decellularized allografts were collected before valve 
      replacement and at 5, 10, 30 and 90 days post-operatively and frozen until 
      required. Tests were performed using the Luminex-based single human leukocyte 
      antigen (HLA)-A, -B, -C and HLA-DR, -DQ antigen microsphere assay. To determine 
      possible immunogenic epitopes, we used the HLAMatchmaker (HLAMM) software if 
      applicable. Decellularized grafts elicited lower levels of anti-HLA class I and 
      II antibody formation after implantation than cellularized allografts. All 
      patients from cellularized group presented donor-specific antibodies class I and 
      II within 3 months of observation period. In HLAMM analysis, the cellularized 
      group had significantly higher numbers of immunogenic epitopes than 
      decellularized group for both class I and II (p: 0.002 - cl I / p: 0.009 - cl II 
      / p: 0.004 - cl I and II). Our findings demonstrate that the anti-HLA antibodies 
      detected in the cellularized group were against donor HLA possible immunogenic 
      epitopes and that in the decellularized group the anti-HLA antibodies were not 
      against donor HLA possible immunogenic epitopes. These findings lead us to 
      suggest that choosing sodium dodecyl sulfate decellularization process is the 
      best alternative to decrease the immunogenicity of allograft valve transplant.
CI  - (c) 2012 John Wiley & Sons A/S.
FAU - Kneib, C
AU  - Kneib C
AD  - Transplant Immunology Laboratory, Pontificia Universidade Catolica do Parana, 
      Curitiba, Brazil. carolina.kneib@pucpr.br
FAU - von Glehn, C Q C
AU  - von Glehn CQ
FAU - Costa, F D A
AU  - Costa FD
FAU - Costa, M T B A
AU  - Costa MT
FAU - Susin, M F
AU  - Susin MF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120525
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (Epitopes)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibody Specificity
MH  - Aortic Valve/*immunology/transplantation
MH  - Epitopes
MH  - Female
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Histocompatibility Antigens Class II/*immunology
MH  - Humans
MH  - Immunity, Humoral
MH  - Isoantibodies/biosynthesis/*immunology
MH  - Male
MH  - Middle Aged
MH  - Pulmonary Valve/*immunology/transplantation
MH  - Tissue Donors
MH  - Transplantation, Homologous
EDAT- 2012/05/29 06:00
MHDA- 2013/04/30 06:00
CRDT- 2012/05/29 06:00
PHST- 2012/05/29 06:00 [entrez]
PHST- 2012/05/29 06:00 [pubmed]
PHST- 2013/04/30 06:00 [medline]
AID - 10.1111/j.1399-0039.2012.01885.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2012 Aug;80(2):165-74. doi: 10.1111/j.1399-0039.2012.01885.x. 
      Epub 2012 May 25.